Table 3. Patient characteristics of and clinical data for serotype IV GBS isolates from infants with invasive GBS disease, Minnesota, USA, January 2000–December 2010*.
| Period | Disease type† | Patient age at diagnosis | Patient outcome | Culture source | Clindamycin susceptibility‡ | Isolate protein profile | Isolate PFGE profile |
|---|---|---|---|---|---|---|---|
| 2001–2009 | Late-onset | 98 d | Survived | Joint fluid | S | C-α and BPS | 37a |
| Late-onset | 30 d | Survived | Blood | S | C-α and BPS | 37 | |
| Late-onset | 9 d | Died | Blood | S | BPS | 37a | |
| Early-onset | 1 d | Survived | Blood | S | None | 40 | |
| Late-onset | 9 d | Survived | Blood | S | BPS | 37a | |
| Early-onset | 2 d | Survived | Blood | S | BPS | 37a | |
| Early-onset | 1 d | Survived | Blood | S | BPS | 37a | |
| 2010 | Early-onset | 1 d | Survived | Blood | R | C-α | 39a |
| Early-onset | Newborn | Survived | Blood | R | C-α | 39c | |
| Early-onset | Newborn | Survived | Blood | R | C-α | 39a | |
| Early-onset | Newborn | Survived | Blood | R | C-α | 39a | |
| Early-onset | Newborn | Survived | Blood | S | BPS | 37a |
*GBS, group B Streptococcus; PFGE, pulsed-field gel electrophoresis; C-α, C-protein α; BPS, group B protective surface protein. †Early-onset, patient age birth–6 days; late-onset, patient age 7–180 days. ‡S, susceptible, MIC <0.25 μg/mL; R, resistant, MIC >1 μg/mL.